Mahesh is the President and CEO of Omega Therapeutics (Nasdaq: OMGA), a clinical-stage biotechnology company pioneering a new field of epigenomic programming to use mRNA therapeutics as programmable epigenetic medicines. At Omega, he has led the translation of completely new science into a drug development and therapeutic platform with a broad pipeline in oncology, regenerative medicine, immunology, inflammatory conditions, and important monogenic conditions. As Omega’s CEO, Mahesh has raised $350 million through private rounds (series A, B, C) and a successful IPO in July 2021. Prior to Omega, he held the position of CEO of Macrolide Pharma. Upon his arrival, Mahesh immediately assessed the science of the company, leadership, core competencies, and pipeline to optimize a path forward for the highest shareholder return.
Before his CEO positions, Mahesh held numerous leadership roles at Novartis Pharmaceuticals most recently as a corporate-level Vice President and US franchise head leading the Oncology solid tumors business, President of Africa, President of Egypt and Regional Vice President of strategy and business development for 95+ emerging markets from Africa to Australia, where he oversaw execution of over 50 partnership deals. He has led over 10 product launches in the U.S. and across global markets. He has had the distinction of successfully leading his teams in Egypt though the military coup of 2013 and Africa through the Ebola crisis of 2014 and the oil-currency crisis of 2015. He over-delivered on business results despite these existential crises.
Prior to entering the pharmaceutical industry, Mahesh worked for the global management consulting firm, McKinsey and Company where he led and worked on projects across pharmaceuticals, medical devices, telecom, technology and private equity.
Mahesh has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology, where he completed his M.S. in engineering, and the University of Bombay, where he completed undergraduate studies in engineering.